Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 6/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.47 |
| ▸ | PDE4A | P27815 | 2/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 7/20 | 0.42 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.42 |
| ▸ | CYP21A2 | P08686 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MGAM | O43451 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | SI | P14410 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.41 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2945457 | 0.99 | CYP19A1 (0.47) | CYP19A1PDE4BPDE4ACYP11B1CYP17A1 | |
| SCHEMBL16089779 | 0.89 | PKM (0.45) | PDE4BPDE4AMGAMGAASI | |
| SCHEMBL2948666 | 0.84 | PDE4B (0.43) | PDE4BPDE4AMGAMGAASI | |
| SCHEMBL13846419 | 0.81 | PDE4A (0.47) | CYP19A1PDE4ACYP11B1CYP17A1CYP11B2 | |
| SCHEMBL4526575 | 0.81 | AGTR2 (0.46) | CYP19A1PDE4BPDE4ACYP11B1CYP17A1 | |
| SCHEMBL2919358 | 0.77 | PDE4A (0.52) | PDE4BPDE4AMGAMGAASI | |
| SCHEMBL2660114 | 0.74 | CYP19A1 (0.69) | CYP19A1CYP11B1CYP11B2POLBTBXAS1 | |
| SCHEMBL2917267 | 0.72 | MYC (0.54) | PDE4BPDE4AMGAMGAASI | |
| SCHEMBL7440005 | 0.71 | PDE4A (0.69) | PDE4BPDE4APKM | |
| SCHEMBL2914411 | 0.71 | PDE4A (0.45) | PDE4BPDE4APOLBMGAMGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8883833-B2 | Substituted benzoazole PDE4 inhibitors for treating inflammatory, cardiovascular and CNS disorders | DECODE GENETICS EHF (IS) | 2014-11-11 | — | — | US | disclosed |
| US-20120207729-A1 | SUBSTITUTED BENZOAZOLE PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS | DECODE GENETICS EHF (IS) | 2012-08-16 | — | — | US | disclosed |
| US-20090130077-A1 | SUBSTITUTED BENZOAZOLE PDE4 INHIBITORS FOR TREATING INFLAMMATORY, CARDIOVASCULAR AND CNS DISORDERS | DECODE GENETICS EHF (IS) | 2009-05-21 | — | — | US | disclosed |
| US-20090130076-A1 | SUBSTITUTED BENZOAZOLE PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS | DECODE GENETICS EHF (IS) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090130076-A1 | SUBSTITUTED BENZOAZOLE PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS | PDE3B, PDE4B, PDE4A | CYP19A1 1322/4885PDE4B 2/4885PDE4A 3/4885 |
| US-20090130077-A1 | SUBSTITUTED BENZOAZOLE PDE4 INHIBITORS FOR TREATING INFLAMMATORY, CARDIOVASCULAR AND CNS DISORDERS | PDE4B, PDE4A, PDE3B | CYP19A1 629/4885PDE4B 1/4885PDE4A 2/4885 |
| US-20120207729-A1 | SUBSTITUTED BENZOAZOLE PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS | PDE3B, PDE4B, PDE4A | CYP19A1 1322/4885PDE4B 2/4885PDE4A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.